GlycoMimetics Highlights Preclinical Data in Oral Presentation at ASH Meeting Demonstrating Impact of GMI-1271 on T Memory Stem Cells
First clinical trial initiated to evaluate mobilization and enrichment of T memory stem and T central memory cells by GMI-1271
"We have shown via our oral presentation at ASH 2015, as well as in
previous studies, that GMI-1271 has an attractive preclinical profile
and, importantly, demonstrates in animal models the capacity to mobilize
and enrich Tscm/cm cells, which are believed to be ideal for use in
adoptive T cell therapy," said
GMI-1271 is a novel and proprietary compound that is an antagonist to
E-selectin, used in combination with chemotherapy in patients with acute
myeloid leukemia (AML). Earlier this year, the
The Phase 1 study will recruit approximately 42 healthy participants at
one center in
The abstract for the oral presentation from ASH 2015 (Abstract #512), entitled "Mobilization of CD8+ Central Memory T-Cells with Enhanced Reconstitution Potential in Mice By a Combination of G-CSF and GMI-1271-Mediated E-Selectin Blockade," is available at ASH's website.
GMI-1271 is an antagonist of E-selectin, a molecule that normally aids
in adhesion of white blood cells to endothelial cells during
inflammation responses, but also can be used by cancer cells to invade
the immune cell system. GMI-1271 is being evaluated as adjunctive
treatment to standard cytotoxic chemotherapy in patients with
hematologic malignancies, particularly in AML, in elderly patients with de
novo AML, and in multiple myeloma.
GlycoMimetics is a clinical stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role.
GlycoMimetics's wholly-owned drug candidate (GMI-1271) for AML and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at www.glycomimetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of the GMI-1271 and the presentation of data.
Actual results may differ materially from those in these forward-looking
statements. For a further description of the risks associated with these
statements, as well as other risks facing
News Provided by Acquire Media